Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
about
In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensisAntibody vs. HIV in a clash of evolutionary titansComprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesMicrobial Cryptotopes are Prominent Targets of B-cell ImmunityAdditive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesHIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentNet positive charge of HIV-1 CRF01_AE V3 sequence regulates viral sensitivity to humoral immunity.Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sitesEvolution and biological characterization of human immunodeficiency virus type 1 subtype E gp120 V3 sequences following horizontal and vertical virus transmission in a single family.A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer.Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usageNeutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans.Shortening of the symptom-free period in rhesus macaques is associated with decreasing nonsynonymous variation in the env variable regions of simian immunodeficiency virus SIVsm during passage.An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.A group of V3 sequences from human immunodeficiency virus type 1 subtype E non-syncytium-inducing, CCR5-using variants are resistant to positive selection pressureInduction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.Characterization of primary isolate-like variants of simian-human immunodeficiency virusImproved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelopeGenetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques.Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India.Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccineStructural dynamics of HIV-1 envelope Gp120 outer domain with V3 loop.Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject
P2860
Q24536041-3EDEBBA4-F244-4351-BB14-7EDE66D60A80Q24536059-BE8473E5-C019-4F2E-AA39-AE69E580D8E4Q24561905-689EB748-2C8D-4BFF-B9FE-2FFC6D7512C1Q27468862-1E0447BD-0582-4202-B713-38E57E7F8FB9Q27469855-F6BA6110-7E33-4CD8-8C36-C8E68F6F401BQ27489000-99022B8C-77A7-4288-BE10-F3B990221FF0Q29619015-C484A75D-7F95-41E4-91ED-BAE6CFC9C2D8Q30355260-67CD0FE6-B2F5-4B6C-B205-19F6A536B590Q33369086-86C0EDE8-AD5D-4D80-B684-53DCF87D4EB6Q33614461-BA4FD7F5-747C-4072-BF2E-F585512443DBQ33645838-65E6D05D-3F2F-4F3D-BAEB-235E526D698BQ33725702-B412870A-1A18-468F-B6C0-68DDF8E63FCEQ33782296-83CEAC06-D8F4-45E8-AE98-7F952E690E6FQ33782556-4B4EEDE3-F449-4B5E-8A18-7C741276938EQ33782608-C92F0E27-50F7-4234-8A0E-EBB455866EBEQ33783949-CFD4BBD9-20B5-4C1D-9DAE-2076DD4A9BD6Q33784679-DA0DC5CB-BA7D-45EF-AD1E-1DEEA2E001B5Q33785510-8EB00DA5-72D6-4179-96F5-B861D2711023Q33786049-6B763C3E-1073-4201-BFB4-AD23456972A3Q33788810-DC66A9AA-6D50-4A50-8109-B6D91EC5B9ACQ33792878-BBBCD5CC-EA9B-49A0-BCA1-55C8017B06E6Q33794744-C80FCB5F-31F4-4E04-8E56-F375BCC2FBF5Q33803217-A924F8AD-4800-4489-A7E4-6F5255E28D4AQ33809112-08AF9559-4ADF-46A0-B39B-8E38CACB30A7Q33813526-7856A723-659B-499D-8BB0-5038AC2ABE95Q33825229-7180F1DC-47C3-4C19-9C4C-B0B568E7B836Q33836042-18FD1E37-74D3-45CD-9432-F78A505C2D9DQ33839402-AAB5784F-B16A-48ED-AF62-99FBBA523D1FQ33842152-DCDFC43E-50CF-4DE2-AE1C-B5387188630AQ33842286-50870B37-61C7-4475-9BAE-8B0ADC9D21DDQ33850612-F546CA7F-59FC-4DE9-A901-8342326CD226Q33887693-552B1EC1-3BB0-47D5-8A3F-C17B03683B7FQ33947008-6C775644-5B5B-4A45-8B00-5A46BA9EAB0CQ33953062-AA4CC521-0DA3-4AF2-90F4-CE586C3060E8Q33961448-7091ACBC-2C6D-46BF-A5A9-A5A10ECD4495Q34083235-E270E03D-7397-47B0-B007-AB6802CE5F75Q34145199-3568F4B1-13B7-462F-8551-A8AAEF283FE2Q34157802-F7A814DB-DC27-438F-B951-80C37B20A0BEQ34280044-093A6D77-46A7-44D3-94D5-B63BDA9DBD90Q34326222-0E6734F8-4B51-45D4-AE3E-31974FF0D52B
P2860
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Cryptic nature of envelope V3 ...... from antibody neutralization.
@ast
Cryptic nature of envelope V3 ...... from antibody neutralization.
@en
type
label
Cryptic nature of envelope V3 ...... from antibody neutralization.
@ast
Cryptic nature of envelope V3 ...... from antibody neutralization.
@en
prefLabel
Cryptic nature of envelope V3 ...... from antibody neutralization.
@ast
Cryptic nature of envelope V3 ...... from antibody neutralization.
@en
P2093
P2860
P1433
P1476
Cryptic nature of envelope V3 ...... from antibody neutralization.
@en
P2093
Bou-Habib DC
Norcross MA
Roderiquez G
P2860
P304
P407
P577
1994-09-01T00:00:00Z